Akero Therapeutics, Inc.
AKRO
株式のランク
#3728
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing... Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
株価
$54.65
最終同期: 2025-12-09
時価総額
$4.50B
変化（1日）
0.00%
変化（1年）
1.50%
国
US
取引 Akero Therapeutics, Inc. (AKRO)
カテゴリー
Healthcare
Akero Therapeutics, Inc.（AKRO）のEPS
September 2025 時点のEPS TTM: $-3.74
Akero Therapeutics, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-3.74です。2023年末には、EPSは$-2.89で、2022年のEPS$-2.87と増加でした。
Akero Therapeutics, Inc.のEPS履歴（2017から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-3.74 | -0.27% |
| 2024 | $-3.75 | 29.76% |
| 2023 | $-2.89 | 0.70% |
| 2022 | $-2.87 | -0.69% |
| 2021 | $-2.89 | 14.68% |
| 2020 | $-2.52 | -13.10% |
| 2019 | $-2.90 | -24.68% |
| 2018 | $-3.85 | 2,306.25% |
| 2017 | $-0.16 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -563.10% |
US
|
|
| $-7.98 | 113.37% |
US
|
|
| $-5.29 | 41.44% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -841.71% |
NL
|
